activity, cytotoxicity, apoptosis, and Aβ aggregation inhibition tests were also performed for selected compounds. The results indicated that compounds 11c, a pentanamide derivative with benzothiazolone core, and 14b, a keton derivative with benzothiazolone core, were considered as promising multi-functional agents for further investigation against AD. The reversibility, kinetic and molecular docking studies
在这项研究中,设计,合成和评估了具有
苯并恶唑酮和
苯并噻唑酮核心的四个系列化合物,作为对抗阿尔茨海默氏病(AD)的多功能药物。另外,为了阐明
苯并恶唑酮/
苯并噻唑酮的羰基的作用,还合成并评价了含
苯并恶唑/
苯并噻唑的类似物。测试了所有最终化合物对
胆碱酯酶的抑制能力及其抗氧化活性。随后,还对所选化合物进行了抗炎活性,细胞毒性,细胞凋亡和Aβ聚集抑制试验。结果表明,化合物11c,具有
苯并噻唑酮核心的戊酰胺衍
生物和14b,具有
苯并噻唑酮核心的酮衍
生物,被认为是有希望的针对AD的进一步研究的多功能药物。还对具有最高AChE 14b(ee AChE IC 50 = 0.34μM,hu AChE IC 50 = 0.46μM)和BChE 11c(eq BChE IC 50 = 2.98μM,hu BChE )的化合物进行了可逆性,动力学和分子对接研究IC 50 = 2.56μM)抑制活性。